TITLE

COMMENTARY: Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease

AUTHOR(S)
Isley, William L.
PUB. DATE
March 2006
SOURCE
ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p34
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on a study which reveals that pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Although glycemic control generally has not been shown to reduce macrovascular events, it is clear that the placebo group did not have adequate glycemic therapy to match that of the active treatment group.
ACCESSION #
20297589

 

Related Articles

  • Pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease.  // ACP Journal Club;Mar/Apr2006, Vol. 144 Issue 2, p34 

    The article focuses on a study which reveals that pioglitazone did not reduce a composite endpoint of macrovascular complications and increased risk for heart failure in type 2 diabetes with macrovascular disease. Randomized placebo-controlled trial was conducted on 5238 patients who had type 2...

  • Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study.  // Cardiovascular Diabetology;2011, Vol. 10 Issue 1, p39 

    The article offers information on the research conducted by the authors related to seven-year mortality in heart failure patients with undiagnosed diabetes. It states that the study observed the patients with type 2 diabetes mellitus and heart failure have adverse clinical outcomes, but the...

  • New risk score for heart failure in T2D.  // Diabetes Digest;2011, Vol. 10 Issue 3, p178 

    The article focuses on the study by R. Pfister and colleagues which shows that the risk prediction score can be used to calculate future heart failure in patients with type 2 diabetes (T2D).

  • Clozapine and refractory diabetes treatment. Galappathie, Nuwan; Harsh, Rajendra // Journal of Diabetes Nursing;2013, Vol. 17 Issue 3, p112 

    Young people with treatment-resistant paranoid schizophrenia may require clozapine, which is a highly potent antipsychotic drug that is recommended when other drugs have failed. Clozapine has significant side effects including potentially fatal agranulocytosis. It has also been implicated in...

  • Thiazolidinediones in Patients with Diabetes Mellitus and Heart Failure: Implications of Emerging Data. Macfarlane, David P.; Fisher, Miles // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 5, p297 

    Individuals with diabetes mellitus have an increased risk of developing heart failure, usually as a consequence of coronary artery disease, although a specific diabetic cardiomyopathy, secondary to a microangiopathy, may also exist. The thiazolidinediones, a relatively new class of...

  • Second-Line Agents for Glycemic Control for Type 2 Diabetes: Are Newer Agents Better? Yuanhui Zhang; McCoy, Rozalina G.; Mason, Jennifer E.; Smith, Steven A.; Shah, Nilay D.; Denton, Brian T. // Diabetes Care;May2014, Vol. 37 Issue 5, p1338 

    OBJECTIVE While metformin is generally accepted as the first-line agent in treatment of type 2 diabetes, there are insufficient evidence and extensive debate about the best second-line agent. We aimed to assess the benefits and harms of four commonly used antihyperglycemia treatment regimens...

  • Pilot study: Hypoglycemic and antiglycation activities of bitter melon (Momordica charantia L.) in type 2 diabetic patients. Trakoon-osot, Wilai; Sotanaphun, Uthai; Phanachet, Pariya; Porasuphatana, Supatra; Udomsubpayakul, Umaporn; Komindr, Surat // Journal of Pharmacy Research;2013, Vol. 6/7 Issue 8, p859 

    Background/Objectives: Bitter melon (Momordica charantia L., MC) has been used as a traditional remedy in diabetics due to its hypoglycemic activity. However, its antihyperglycemic effect and antiglycation activity have been demonstrated in vitro and in animal experiments, but not in a long-term...

  • Spice and Sugar: Curcumin and Type 2 DM. Greenfield, Russell H. // Integrative Medicine Alert;Sep2012, Vol. 15 Issue 9, p106 

    Strategies aimed at preventing type 2 diabetes mellitus (DM) typically focus primarily on diet and lifestyle changes, together with select drug therapy where appropriate. The rationale is reasonable, but results have been largely disappointing. An increasing number of people are diagnosed with...

  • Effects of pentoxifylline and pentosan polysulphate combination therapy on diabetic neuropathy in type 2 diabetes mellitus. Laczy, Boglárka; Cseh, Judit; Mohás, Márton; Markó, Lajos; Tamaskó, Mónika; Kőszegi, Tamás; Molnár, Gergő; Wagner, Zoltán; Wagner, Lászl&c#x00F3;; Wittmann, István // Acta Diabetologica;Jun2009, Vol. 46 Issue 2, p105 

    Vascular dysfunction, including impaired perfusion has a pivotal role in the pathogenesis of microvascular complications in diabetes mellitus. Both pentoxifylline (PF) and pentosan polysulphate (PPS) are known to improve microcirculation. Antioxidant and antiproteinuric effects of PF are also...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics